Multiagent CHOP protocols, which vary in doses, scheduling, and dose intensity, are frequently recommended.
The University of Wisconsin–Madison protocol is often recommended for clients choosing a combination protocol because it has high complete remission rates and remission duration and is generally well tolerated.1 Clients typically feel treatment was worthwhile and that the dog’s quality of life not only improved from treatment but also was good during treatment.1
Alternatives to CHOP protocols (eg, single-agent doxorubicin, single-agent oral lomustine, the COP protocol) are available, but they generally have lower response rates and shorter remission durations.1
In April, the FDA conditionally approved Tanovea-CA1 (rabacfosadine), a new chemotherapeutic agent to treat lymphoma in dogs that has, to date, demonstrated reasonable efficacy and complete and acceptable safety.6 The overall response rate in clinical studies was 77%.6 A more recent study examined its use in combination with doxorubicin and found an overall response rate of 84%.7
Tanovea can be used as a first-line therapy and in dogs that have failed or relapsed with prior treatment. The chemotherapeutic should be administered under the supervision of a veterinarian experienced in the use of cancer therapeutics, and standard measures for the safe handling of cytotoxic drugs should be used.
Consultation with or referral to an oncologist is recommended for all lymphoma cases because these specialists are knowledgeable about the newest treatments and prognostic data and can help clients explore all options and choose the best treatment for their specific pet and situation.